Prostate Cancer Outcomes at KFSYSCC
Between 2015-2019, the five-year survival rate for prostate cancer at KFSYSCC was 86.8% vs 68.5% for other hospitals in Taiwan.
Basic Information and Distribution of 2,763 Prostate Cancer Patients at KFSYSCC from 1990-2019
| Total | 1990-1994 | 1995-1999 | 2000-2004 | 2005-2009 | 2010-2014 | 2015-2019 | |
|---|---|---|---|---|---|---|---|
| n | 2,763 | 24 (2%) | 158 (6%) | 420 (15%) | 713 (26%) | 784 (28%) | 664 (24%) |
| Age | |||||||
| Mean/Median | 68/68 | 70/69 | 69/69 | 69/70 | 68/69 | 68/67 | 68/69 |
| Range | 15-98 | 61-89 | 45-88 | 15-90 | 41-92 | 45-90 | 43-98 |
| Q1-Q3 | 63-74 | 66-74 | 65-74 | 64-74 | 62-74 | 62-73 | 63-74 |
| Stage (%) | |||||||
| 0 | 1 (0.04%) | 0 (0%) | 1 (1%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| I | 96 (3%) | 1 (4%) | 1 (1%) | 2 (1%) | 1 (0.1%) | 50 (6%) | 41 (6%) |
| II | 909 (33%) | 6 (25%) | 35 (22%) | 142 (34%) | 270 (38%) | 261 (33%) | 195 (29%) |
| III | 941 (34%) | 5 (21%) | 28 (18%) | 108 (26%) | 274 (38%) | 275 (35%) | 251 (38%) |
| IV | 644 (23%) | 9 (38%) | 33 (21%) | 81 (19%) | 153 (21%) | 193 (25%) | 175 (26%) |
| Unknown | 172 (6%) | 3 (13%) | 60 (38%) | 87 (21%) | 15 (2%) | 5 (1%) | 2 (0.3%) |
Based on KFSYSCC's cancer registry data from 1990 to 2019, there were a total of 2,763 analytic prostate cancer cases. The average and median ages were 68 and 68 years old, respectively, with the youngest patient being 15 years old and the oldest at 96 years old; the interquartile range (Q1-Q3) spanned 63-74 years. When examined by stage, 1 patient was stage 0 (0.04%), 96 were stage I (3%), 909 were stage II (33%), 941 were stage III (34%), and 644 were stage IV (23%). The table below presents the basic patient information and stage distribution, categorized by the year of diagnosis.
Survival Curves for 2,763 Prostate Cancer Patients (1990-2019), Stratified by Year of Diagnosis
From 1990 to 2019, the chart illustrates the five-year observed survival rates for 2,763 prostate cancer patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for cervical cancer increased from 79% in 1990-1994 to 87% in 2015-2019, while the ten-year survival rate rose from 62% in 1990-1994 to 66% in 2010-2014.
Treatment Methods and Stages for 664 Prostate Cancer Patients at KFSYSCC (2015-2019)
| Treatment Type | Total | Stage I | Stage II | Stage III | Stage IV | Unknown |
|---|---|---|---|---|---|---|
| Total | 664 | 41 | 195 | 251 | 175 | 2 |
| Surgical Treatment | 411 (62%) | 21 (51%) | 154 (79%) | 198 (79%) | 36 (21%) | 2 (100%) |
| Radiation Therapy | 92 (14%) | 1 (2%) | 20 (10%) | 24 (10%) | 47 (27%) | 0 (0%) |
| Chemotherapy | 13 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 13 (7%) | 0 (0%) |
| Targeted Therapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Hormone Therapy | 435 (66%) | 1 (2%) | 64 (33%) | 199 (79%) | 170 (97%) | 1 (50%) |
| Immunotherapy | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
| Palliative Care | 19 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 19 (11%) | 0 (0%) |
| Bone Marrow/Stem Cell Transplant | 2 (0.3%) | 0 (0%) | 0 (0%) | 1 (0.4%) | 1 (1%) | 0 (0%) |
| No Record of Initial Treatment Reported | 30 (5%) | 19 (46%) | 7 (4%) | 3 (1%) | 1 (1%) | 0 (0%) |
Between 2015 and 2019, there were a total of 664 analytic prostate cancer cases, including 41 patients in stage I, 195 in stage II, 251 in stage III, and 175 in stage IV. In terms of treatment methods, 411 patients (62%) underwent surgical treatment, 92 (14%) received radiation therapy, 13 (2%) underwent chemotherapy, 435 (66%) received hormone therapy, 19 (3%) underwent palliative care, 2 (0.3%) received bone marrow or stem cell transplantation, and 30 (5%) had no record of initial treatment reported.
Five-Year Survival Rates of 664 Prostate Cancer Patients by Stage (2015-2019)
KFSYSCC’s 2015-2019 five-year observed survival rates for 664 prostate cancer patients, stratified by stage, are presented in the following chart. As shown in the graph, the five-year survival rate is 100% for stage 1, 95% for stage 2, 94% for stage 3, and 65% for stage 4.